Viridian Therapeutics Inc (VRDN)

$17.04 +0.18 (1.07%)
Market Cap 1.77B
Revenue (ttm) 70.85M
Net Income (ttm) -342.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -483.56%
Debt to Equity Ratio 0.08
Volume 2,190,639
Avg Vol 3,028,500
Day's Range N/A - N/A
Shares Out 103.08M
Stochastic %K 54%
Beta 0.82
Analysts Strong Sell
Price Target $34.06

Company Profile

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 272 4600
Fax: 617 272 4601
Address:
221 Crescent Street, Suite 103A, Waltham, United States
HamBoneXoXo
HamBoneXoXo May. 13 at 8:47 PM
$VRDN In 18 now; what’s up?
1 · Reply
FilingTracker
FilingTracker May. 13 at 8:34 PM
$VRDN Massive $20 million purchase by 10% owner: https://www.sec.gov/Archives/edgar/data/1590750/000110465926060294/xslF345X06/tm2614357-1_4seq1.xml
0 · Reply
HamBoneXoXo
HamBoneXoXo May. 13 at 5:45 PM
$VRDN Over a billion in cash; heavy institutions; last offering at 17/24.5, pdufa end June, been consolidating, looks good to me
0 · Reply
SoYeonPicks
SoYeonPicks May. 13 at 9:30 AM
$VRDN let's take this back up
0 · Reply
Tdorsey1776
Tdorsey1776 May. 12 at 8:14 PM
$VRDN Look at that long term chart? It screams $$$$$
0 · Reply
GreenorGo
GreenorGo May. 12 at 4:19 PM
$VRDN Next catalyst is June 30, expecting this to not have much movement until then. ⏱️⏱️
0 · Reply
SoYeonPicks
SoYeonPicks May. 12 at 3:14 PM
$VRDN in for 1600 shares
0 · Reply
GreenorGo
GreenorGo May. 11 at 5:46 PM
$VRDN Anyone have any ideas as to when the next catalyst may be??? It’ll be time to take off when that happens 🔥🔥🔥
2 · Reply
HamBoneXoXo
HamBoneXoXo May. 11 at 2:46 PM
$VRDN Never understood the need for the raise while having 800 plus in cash.
0 · Reply
Tdorsey1776
Tdorsey1776 May. 11 at 2:27 PM
$VRDN $NVCR
2 · Reply
Latest News on VRDN
Viridian Therapeutics price target lowered to $39 from $48 at Stifel

2026-05-13T18:58:41.000Z - 2 hours ago

Viridian Therapeutics price target lowered to $39 from $48 at Stifel

Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00

2026-05-07T11:24:55.000Z - 6 days ago

Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00

Viridian Therapeutics price target raised to $34 from $30 at RBC Capital

2026-05-07T06:49:01.000Z - 6 days ago

Viridian Therapeutics price target raised to $34 from $30 at RBC Capital

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

May 6, 2026, 11:13 PM EDT - 6 days ago

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

May 5, 2026, 4:05 PM EDT - 8 days ago

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

Viridian Therapeutics Transcript: Study result

May 5, 2026, 8:00 AM EDT - 8 days ago

Viridian Therapeutics Transcript: Study result

Viridian announces REVEAL-2 phase 3 study met primary endpoint

2026-05-05T11:38:18.000Z - 8 days ago

Viridian announces REVEAL-2 phase 3 study met primary endpoint

Viridian Therapeutics reports Q1 EPS (90c), consensus ($1.09)

2026-05-05T11:26:55.000Z - 8 days ago

Viridian Therapeutics reports Q1 EPS (90c), consensus ($1.09)

Viridian eye disease drug benefits chronic patients in late-stage trial

May 5, 2026, 7:05 AM EDT - 8 days ago

Viridian eye disease drug benefits chronic patients in late-stage trial

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 5, 2026, 7:01 AM EDT - 8 days ago

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

May 5, 2026, 7:00 AM EDT - 8 days ago

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

Viridian Therapeutics price target lowered to $33 from $36 at Truist

2026-04-21T15:48:24.000Z - 22 days ago

Viridian Therapeutics price target lowered to $33 from $36 at Truist

Viridian Therapeutics price target lowered to $24 from $32 at Evercore ISI

2026-04-13T13:57:38.000Z - 4 weeks ago

Viridian Therapeutics price target lowered to $24 from $32 at Evercore ISI

Viridian Therapeutics price target lowered to $36 from $40 at Truist

2026-04-08T12:32:05.000Z - 5 weeks ago

Viridian Therapeutics price target lowered to $36 from $40 at Truist

AMGN

Viridian Therapeutics price target lowered to $31 from $37 at Wedbush

2026-04-08T11:48:42.000Z - 5 weeks ago

Viridian Therapeutics price target lowered to $31 from $37 at Wedbush

AMGN

Viridian Therapeutics price target lowered to $30 from $42 at RBC Capital

2026-04-07T13:56:27.000Z - 5 weeks ago

Viridian Therapeutics price target lowered to $30 from $42 at RBC Capital

Viridian Therapeutics removed from Best Ideas List at Wedbush

2026-04-07T11:50:43.000Z - 5 weeks ago

Viridian Therapeutics removed from Best Ideas List at Wedbush

Leerink sees weakness in Viridian Therapeutics shares as ‘overdone’

2026-04-06T17:30:48.000Z - 5 weeks ago

Leerink sees weakness in Viridian Therapeutics shares as ‘overdone’

AMGN

Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.

Apr 6, 2026, 12:10 PM EDT - 5 weeks ago

Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.

AMGN

Viridian sinks after Amgen thyroid eye disease study hits endpoints

2026-04-06T14:46:07.000Z - 5 weeks ago

Viridian sinks after Amgen thyroid eye disease study hits endpoints

Evercore cuts Viridian price target, removes from ‘Tactical Outperform’ list

2026-04-02T11:53:35.000Z - 5 weeks ago

Evercore cuts Viridian price target, removes from ‘Tactical Outperform’ list

AMGN

Viridian Therapeutics price target lowered to $37 from $44 at Wedbush

2026-03-31T11:58:41.000Z - 6 weeks ago

Viridian Therapeutics price target lowered to $37 from $44 at Wedbush

Viridian Therapeutics price target lowered to $20 from $29 at Wells Fargo

2026-03-31T10:52:48.000Z - 6 weeks ago

Viridian Therapeutics price target lowered to $20 from $29 at Wells Fargo

Viridian Therapeutics price target lowered to $36 from $41 at Goldman Sachs

2026-03-31T10:20:58.000Z - 6 weeks ago

Viridian Therapeutics price target lowered to $36 from $41 at Goldman Sachs

Viridian Therapeutics Transcript: Study result

Mar 30, 2026, 8:00 AM EDT - 6 weeks ago

Viridian Therapeutics Transcript: Study result

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

Mar 30, 2026, 7:01 AM EDT - 6 weeks ago

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

Viridian Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:00 AM EDT - 2 months ago

Viridian Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Viridian Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 2 months ago

Viridian Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 7:01 AM EST - 2 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 8, 2026, 4:01 PM EST - 4 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Prepares for Transformational 2026

Jan 6, 2026, 7:01 AM EST - 4 months ago

Viridian Therapeutics Prepares for Transformational 2026

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Dec 22, 2025, 7:00 AM EST - 5 months ago

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Viridian Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 9:35 AM EST - 5 months ago

Viridian Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Viridian Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 3:00 AM EST - 6 months ago

Viridian Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Viridian Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 9:20 AM EST - 6 months ago

Viridian Therapeutics Transcript: Stifel 2025 Healthcare Conference

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 5, 2025, 7:01 AM EST - 6 months ago

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Nov 3, 2025, 7:01 AM EST - 6 months ago

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Oct 21, 2025, 11:24 PM EDT - 7 months ago

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering

Oct 21, 2025, 4:01 PM EDT - 7 months ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

Oct 20, 2025, 7:30 AM EDT - 7 months ago

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

Sep 15, 2025, 7:01 AM EDT - 8 months ago

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 6:30 AM EDT - 10 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

Jul 30, 2025, 4:00 AM EDT - 10 months ago

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2025, 7:00 AM EDT - 11 months ago

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 8:40 AM EDT - 1 year ago

Viridian Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Viridian Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 7:35 AM EDT - 1 year ago

Viridian Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

May 30, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

May 20, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

May 7, 2025, 4:15 PM EDT - 1 year ago

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Apr 7, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 12, 2025, 10:00 AM EDT - 1 year ago

Viridian Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Viridian Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 9:10 AM EST - 1 year ago

Viridian Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Jan 8, 2025, 7:00 AM EST - 1 year ago

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Dec 16, 2024, 7:10 AM EST - 1 year ago

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Dec 16, 2024, 7:00 AM EST - 1 year ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Dec 13, 2024, 6:00 PM EST - 1 year ago

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Nov 12, 2024, 7:00 AM EST - 1 year ago

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Sep 11, 2024, 11:25 PM EDT - 1 year ago

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Sep 10, 2024, 4:01 PM EDT - 1 year ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Sep 10, 2024, 7:18 AM EDT - 1 year ago

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Sep 9, 2024, 4:01 PM EDT - 1 year ago

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:15 AM EDT - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 11, 2024, 8:40 AM EDT - 2 years ago

Viridian Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Jun 11, 2024, 6:00 AM EDT - 2 years ago

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Viridian Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 5:00 PM EDT - 2 years ago

Viridian Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

May 31, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

Viridian Therapeutics Transcript: Bank of America Health Care Conference 2024

May 15, 2024, 7:35 PM EDT - 2 years ago

Viridian Therapeutics Transcript: Bank of America Health Care Conference 2024

Viridian Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 14, 2024, 8:30 AM EDT - 2 years ago

Viridian Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

May 10, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

Viridian Therapeutics Earnings Call Transcript: Q1 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics Earnings Call Transcript: Q1 2024

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

May 8, 2024, 7:00 AM EDT - 2 years ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

May 7, 2024, 7:33 PM EDT - 2 years ago

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Viridian Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 11, 2024, 2:00 PM EDT - 2 years ago

Viridian Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 8:00 AM EST - 2 years ago

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 4:01 PM EST - 2 years ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Feb 16, 2024, 8:00 AM EST - 2 years ago

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

Jan 17, 2024, 10:00 PM EST - 2 years ago

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

Viridian Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 11, 2024, 10:30 AM EST - 2 years ago

Viridian Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

Jan 8, 2024, 8:00 AM EST - 2 years ago

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

HamBoneXoXo
HamBoneXoXo May. 13 at 8:47 PM
$VRDN In 18 now; what’s up?
1 · Reply
FilingTracker
FilingTracker May. 13 at 8:34 PM
$VRDN Massive $20 million purchase by 10% owner: https://www.sec.gov/Archives/edgar/data/1590750/000110465926060294/xslF345X06/tm2614357-1_4seq1.xml
0 · Reply
HamBoneXoXo
HamBoneXoXo May. 13 at 5:45 PM
$VRDN Over a billion in cash; heavy institutions; last offering at 17/24.5, pdufa end June, been consolidating, looks good to me
0 · Reply
SoYeonPicks
SoYeonPicks May. 13 at 9:30 AM
$VRDN let's take this back up
0 · Reply
Tdorsey1776
Tdorsey1776 May. 12 at 8:14 PM
$VRDN Look at that long term chart? It screams $$$$$
0 · Reply
GreenorGo
GreenorGo May. 12 at 4:19 PM
$VRDN Next catalyst is June 30, expecting this to not have much movement until then. ⏱️⏱️
0 · Reply
SoYeonPicks
SoYeonPicks May. 12 at 3:14 PM
$VRDN in for 1600 shares
0 · Reply
GreenorGo
GreenorGo May. 11 at 5:46 PM
$VRDN Anyone have any ideas as to when the next catalyst may be??? It’ll be time to take off when that happens 🔥🔥🔥
2 · Reply
HamBoneXoXo
HamBoneXoXo May. 11 at 2:46 PM
$VRDN Never understood the need for the raise while having 800 plus in cash.
0 · Reply
Tdorsey1776
Tdorsey1776 May. 11 at 2:27 PM
$VRDN $NVCR
2 · Reply
Merlintrader
Merlintrader May. 9 at 1:05 PM
$VERA 3 Biotech Stocks Facing Near-Term FDA Catalysts: MannKind ($MNKD), Viridian Therapeutics ($VRDN) and Vera Therapeutics https://www.merlintrader.com/biotech-fda-catalysts-near-term/
0 · Reply
athebeast
athebeast May. 8 at 3:28 PM
$VRDN Left my short position open for the week I'm now up over 20k thank you $VRDN 🙏🙏🙏
0 · Reply
athebeast
athebeast May. 8 at 3:28 PM
$VRDN Oh ya'll bulls have no brain alright 🤑🤑🤑
0 · Reply
athebeast
athebeast May. 8 at 3:27 PM
$VRDN Over 5k profit shorting this, $14 next!!! 🔻🔻🔻
0 · Reply
HamBoneXoXo
HamBoneXoXo May. 7 at 5:46 PM
$VRDN Offering closing on Monday
0 · Reply
HamBoneXoXo
HamBoneXoXo May. 7 at 5:45 PM
$VRDN Interesting: conversion price of $24.65 at a 1.75% interest due every six month with 2032 maturity
0 · Reply
HamBoneXoXo
HamBoneXoXo May. 7 at 4:44 PM
$VRDN Does anyone understand the structure of this convertible offering? I am interested in the interest rate and the conversion price. Thanks
1 · Reply
Tdorsey1776
Tdorsey1776 May. 7 at 11:50 AM
$VRDN Offering oversubscribed...now $350MM
0 · Reply
Tdorsey1776
Tdorsey1776 May. 7 at 12:21 AM
$VRDN Im convinced there is confusion in the market. Those not performing extensive DD are missing the big picture.
0 · Reply
HamBoneXoXo
HamBoneXoXo May. 6 at 11:59 PM
$VRDN $762 mil end of March cash plus $250 mil plus now = just over the billion in cash. And they burn pretty good too. This is nearly 95% institutions. As solid as it may get and the development stage moving forward nicely soon into commercialization.
1 · Reply
Tdorsey1776
Tdorsey1776 May. 6 at 7:42 PM
$VRDN Why the sell pressure? Could be the $250MM convertible note offering. THe most likely check writers will be the current largest inst holders. They will sell common to buy conv notes..... We shall see if it subsides. GLTA
1 · Reply
Astrid00
Astrid00 May. 6 at 7:26 PM
$VRDN
0 · Reply